Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-200T(P) with Gemcitabine and Nab-Paclitaxel in Resectable Pancreatic Cancer
NCT05624918Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC). Primary endpoints: 2 Year Overall Survival and Rate of Resection at 4 years. Started Jul 2024; status: recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05624918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624918.